Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin's Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study.

MLA

Wang, Tianyou, et al. “Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin’s Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-Center, Interventional Study.” Drugs in R&D, vol. 23, no. 2, June 2023, pp. 129–40. EBSCOhost, https://doi.org/10.1007/s40268-023-00420-y.

APA

Wang, T., Zhu, X., Chen, Y., Shen, S., Tang, Y., Zhang, J., He, Y., Zhang, H., Gao, J., Fang, J., Liu, R., Wu, X., Sun, J., & Zhang, M. (2023). Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin’s Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study. Drugs in R&D, 23(2), 129–140. https://doi.org/10.1007/s40268-023-00420-y

Chicago

Wang, Tianyou, Xiaofan Zhu, Yumei Chen, Shuhong Shen, Yongmin Tang, Jingying Zhang, Yingyi He, et al. 2023. “Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin’s Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-Center, Interventional Study.” Drugs in R&D 23 (2): 129–40. doi:10.1007/s40268-023-00420-y.